KR20190033129A - Antiviral composition comprising of fermented Isatis indigotica root extract and its therof - Google Patents

Abstract

The present invention relates to a composition for preventing or treating a virus infectious disease, which comprises a rosemary root extract, and more particularly, to a composition for preventing or treating a virus infection causing a human infectious disease in a fermentation broth obtained by fermenting a rosemary root extract, , Herpes simplex virus causing herpes zoster, coronavirus causing respiratory disease, myocarditis, skin rash, etc., and enterovirus causing aquatic diseases, thereby confirming that the above fermentation broth is effective ingredient To a composition for preventing or treating a viral infection disease.

Description

[0001] The present invention relates to a composition for preventing or treating a virus infectious disease comprising a fermented root extract of Root Root Root Extract,

The present invention relates to a composition for preventing and treating viral infection, which comprises a fermentation broth obtained by fermenting Root Root Root Extract as an active ingredient.

Viruses cause a wide variety of diseases and their symptoms vary according to the type of virus. The viruses causing respiratory diseases are influenza virus, coronavirus, rhinovirus, and the virus causing diarrheal infection is rotavirus, enterovirus, immunological disease is retrovirus, cancer-causing virus is adenovirus, papilloma virus B and C hepatitis viruses. In addition, herpes simplex virus may cause herpes to the face or genital skin, and herpes simplex virus causes herpes zoster.

Enteroviruses are divided into the poliovirus group, the Kosaki virus group, and the enterovirus group, with an estimated 50 million patients worldwide with enterovirus infection [Morens DM and Pallansch MA1995. In; Human enterovirus infections. Robalt HA (ed) Washington, DC, ASM Press, pp3-23]. Polio viruses cause colds and polio [Pallansch MA 2003. In: infectious diseases. Gorbach SL, Barlett JG, Blacklow NR (eds). Philadelphia: Lippincott, Williams and Wilkins, pp. 2347-2057], Kosaki viruses are aseptic myelitis or encephalitis [Chonmaitree T. et al., 1981. Pediatrics. 489-493], acute muscle paralysis, myocarditis [Fujioka S, et al. 2001. Biodrugs. 15 (12): 791-799], type I diabetes [Green J et al. 2004. Diabet Med. 21 (6): 507-514], skin rash [Moreira RC et al., 1995. Rev Inst Med Trop Sao Paulo. 37 (3): 235-238], enteroviruses are the cause of hand-foot disease [Chang LY et al., 1998. Lancet 352: 367-368].

Influenza viruses are influenza A, B, and C viruses. Among them, influenza A virus and influenza B virus are the most frequent influenza viruses. Thus, each year the flu vaccine is produced in the form of a mixture of two A viruses and one B virus. Influenza accounts for one billion patients every year, causing severe respiratory illness and death. In particular, pandemic influenza has a higher mortality rate, with 15 to 50 million deaths occurring during the pandemic in 1918, 2 million deaths in 1957, and 1 million deaths in 1968. As the H5N1 strain of avian influenza virus is reported to be infected with humans, the number of cases of avian influenza virus infection has increased recently, and the possibility of avian influenza virus pandemic is increasing [G Juckett. 2006. American Family Physician 74 (5) 785-790].

Coronavirus has been reported to cause respiratory illness (HCoV-229E) in humans, hepatitis symptoms (MHV-A59) in mice, severe diarrhea symptoms in pigs (TGE-Purdue 115, PED- CV777) The cattle cause respiratory disease (BCoVENT), and the SARS virus in 2003 caused severe respiratory disease in humans.

It is the roots of the cabbage plant, Daechung [Indigo] Isatistinctoria L ... Daechung is planted in various places. It has been generally used as oriental medicine. It is dried in the sun with its roots in fall, and its taste is good and its quality is cold. It is mainly known to lower the heat, detoxify it, and eliminate the blood fever (hemorrhagic fever).

However, there is no known method for directly using the extract of Pan Ram Root. However, there is no known effect of directly increasing the viral infection and therapeutic effect when fermented.

As a result, the present inventors have found that a herpes virus causing a genital disease or a malignant disease, a herpes simplex virus causing herpes zoster, a herpes simplex virus causing herpes zoster virus, Corn virus, myocarditis, skin rash and the like, which cause respiratory diseases, and enterovirus causing aquatic diseases, thereby preventing or treating a viral infection disease containing the fermentation broth as an active ingredient The present invention has been completed.

The present invention relates to a composition for preventing or treating viral infectious diseases, and more particularly, to a composition for preventing or treating viral infectious diseases, which comprises a rosemary root extract, and more particularly, to a composition for preventing or treating viral infectious disease by using a fermentation broth fermented with fermentation yeast The present invention relates to a herpes virus which causes genital diseases or bulbitis, herpes simplex virus causing herpes zoster, coronavirus causing respiratory diseases, myocarditis, skin rash and the like. The present invention provides a composition for preventing or treating a viral infection disease containing the above fermentation broth as an active ingredient by confirming that it exhibits a proliferation inhibitory activity against enterovirus causing a causative virus.

In summary, the present invention provides a composition for preventing or treating viral infectious diseases, which comprises a rosemary root extract, which comprises a herpes virus causing viral genital disease or bulbitis, herpes simplex virus causing herpes zoster, The present invention provides a composition for preventing or treating a viral infection disease containing the fermentation broth as an active ingredient by confirming that it exhibits an antiproliferative activity against enterovirus causing causative diseases such as coronavirus, myocarditis, skin rash, Can be provided.

FIG. 1 shows a confocal laser microscope photograph showing the inhibition of the virus from adhering to a cell membrane of a mammalian cell using a fermentation broth of the Pan Ram Root Extract of the present invention.

Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not to be construed as limiting the scope of the present invention. It will be self-evident.

For the purpose of the present invention, the virus is selected from the group consisting of Herpes simplex virus, Herpes zoster virus, Coxsackie virus, Enterovirus, Influenza virus, Coronavirus Coronavirus). Influenza viruses include influenza A, B, and C viruses. Coronaviruses include human coronavirus (HCoV-229E), porcine coronavirus, Bovine coronaviruses, and SARS-CoV. Herpes viruses include herpes simplex type 1 and type 2, and herpes simplex virus.

The term "anti-virus activity" in the present invention means the above-mentioned enterovirus, influenza virus, coronavirus, more specifically, various subtypes and variants of enteroviruses belonging to the enterovirus, polioviruses, Various subtypes and variants of influenza A, B, and C viruses in the virus, various subtypes and variants of coronavirus, porcine coronavirus, and SARS coronavirus belonging to the coronavirus, and herpes viruses are herpes simplex type 1 Type 2 and herpes simplex virus, and the ability to inhibit viral particles from infecting host cells, that is, the ability of viral particles to adhere to the cell membrane of a host cell to inhibit entry into cells. As a result, the viruses inhibit the mechanism necessary for replication or propagation of viral particles using host cells, and thus have antiviral activity.

1 of the present invention, the antiviral activity of the present invention was analyzed as a result of confirming whether or not a virus was infected to a mammalian cell treated with the virus over time, thereby inhibiting the attachment of the virus to the cell membrane.

The present invention is characterized by providing a composition for preventing and treating an antiviral infectious disease using as an active ingredient a filter solution of a fermentation broth fermented by fermenting yeast in a fermented broth root extract.

The composition of the present invention may contain a fermentation broth obtained by fermenting the broth roots extract solution, in addition to the filter solution or the undiluted solution, pharmaceutically acceptable carriers. The pharmaceutically acceptable carrier may be a binder, a lubricant, a disintegrant, an excipient, a solubilizing agent, a dispersing agent, a stabilizer, a suspending agent, a coloring matter, a perfume or the like in the case of oral administration. A solubilizing agent, an isotonic agent, a stabilizer and the like may be mixed and used. In the case of topical administration, a base, an excipient, a lubricant, a preservative and the like may be used. Formulations of the pharmaceutical compositions of the present invention may be prepared in a variety of ways by mixing with pharmaceutically acceptable carriers as described above. For example, it can be prepared in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers and the like in the case of oral administration, and in the case of injections, unit dosage ampoules or a plurality of dosage forms.

The present invention also provides another aspect of the present invention to provide an antiviral cosmetic product and an external preparation for skin comprising, as an active ingredient, a filter solution of a fermentation broth fermented by fermenting yeast in a fermented broth root extract.

The present invention also provides another aspect of the present invention to provide an antiviral health food containing as an active ingredient a filter solution of a fermentation broth fermented by inoculation with a fermentation yeast in a root of Root Root Extract.

The food of the present invention may be formulated into powders, granules, tablets, capsules or drinks by mixing with the appropriate carrier, excipient or auxiliary active ingredient in addition to the filter liquor of the fermentation broth of Root Root Root Extract. Suitable carriers, excipients and diluents for use in formulating the food composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, tragacanth gum, gelatin, calcium silicate , Microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methyl and propylhydroxybenzoate, talc, magnesium stearate or mineral oil and the like. To further commercialize the food of the present invention, it may further comprise a lubricant, a wetting agent, an emulsifier and a suspending agent, an antiseptic, a sweetener or a flavoring agent.

In the present invention, the fermentation is carried out by using a Pan Ram Root Extract as a substrate to produce lactic acid bacteria, specifically, Lactobacillus rhamnosus, Lactobacillus acidophilus, Lactobacillus plantarum and Bifidobacterium Bifidobacterium bifidum, Lactobacillus acidophilus, Lactobacillus acidophilus, Lactobacillus bulgaricus, Lactobacillus bulgaricus, Lactobacillus bulgaricus, Lactobacillus bulgaricus, Lactobacillus bulgaricus, Bifidobacterium bifidum, or yeast, wherein at least one yeast selected from the group consisting of rhamnosus, Lactobacillus plantarum, Lactobacillus reuteri, Lactobacillus confusus, Lactobacillus fermentum, Lactobacillus brevis, Leuconostoc mesenteroides, Leuconostoc mesenteroides, Leuconostoc sp, Pediococcus acidilactici and Pediococcus pentosaseus is added Steps to the inoculation; 1 to 3 days at 35 to 45 ° C: second fermentation at 2 to 6 ° C for 12 to 36 hours to prepare a fermentation broth.

As used herein, the term "prevention" means any action that inhibits or slows the onset of a viral infection by administration of the composition. In the present invention, the term "treatment" means any action that improves or alleviates symptoms caused by a virus infection by the administration of the composition.

Hereinafter, the present invention will be described in detail.

Example

Throughout this specification, "%" used to denote the concentration of a particular substance is intended to include solids / solids (wt / wt), solid / liquid (wt / The liquid / liquid is (vol / vol)%.

REFERENCE EXAMPLE 1 Preparation of Root Root Extract

In a round flask equipped with a reflux condenser tube, 1 L of distilled water was added to a sample of 100 g of Pansang root, and the extract was repeatedly extracted three times for 3 hours in a water bath at 80 캜. The extract was filtered through a filter paper, And used as a sample in the experimental example.

Reference Example 2: Fermentation of Root Root Extract Solution

Saccharomyces cerevisiae was activated in a YM solid medium at 25 ° C to 50 ° C for 24 hours, inoculated into a sterilized YM liquid medium after one colony, and cultured in a 25 ° C to 50 ° C incubator for 24 hours. do.

Saccharomyces cerevisiae bacteria preliminarily cultivated in a liquid medium containing 1 to 90% by weight of Pansu root root extract is added so as to have a concentration of 10 ⁷ to 10 ⁸ CFU / ml, followed by primary fermentation at 35 to 45 ° C for 1 to 3 days And then fermented again at 2-6 ° C for 12-36 hours to prepare a fermented product.

The fermentation was terminated by heating at 100 ° C for 40 minutes to induce the loss of the bacteria. The precipitate was removed using a centrifuge and the supernatant was collected, or the filtered supernatant was used.

The prepared fermentation broth was mixed with MEM in the same amount as the culture medium for animal cell culture, and then filtered through a 0.22 ㎛ filter to remove the bacteria (solution of the fermentation broth).

Reference Example 3: Culture of virus

Influenza A virus [A / WS / 33] and influenza B virus [B / Lee / 40] used for antiviral activity analysis, examples of enteroviruses include Kosaki A16 virus, Kosaki B3 virus, Kosaki B4 virus, Virus 71 (EV71), herpes simplex types 1 and 2 (Human Herpesvirus 1/2, VR-734, 1383) as herpes virus and herpes zoster were purchased from ATCC. Influenza A virus and influenza B virus were proliferated in MDCK cells. The enteroviruses were Kosaki A16 virus, Kosaki B3 virus, Kosaki B4 virus, Enterovirus 71, Vero cells, and herpes viruses in NIH3T3-E1 cells And the virus titers corresponding to TCID50 were calculated.

Example 1: Antiviral potency test of a fermented broth filter solution against Kosaki virus

To measure the ability of the fermentation broth filter to inhibit virus growth, 2 × 10 ⁴ Vero cells were placed in each well of a 96-well plate and cultured for 24 hours. After 24 hours, the culture supernatant of each well was removed, and 90 쨉 l of one kind of Kosaki virus A16 and 20 kinds of Kosaki B virus (B3, B4) virus diluted to TCID 50 were added to each well And then 10 μl of the fermentation broth filtrate solution mixture prepared in Reference Example 2 was added to each well (final concentration of the fermentation broth solution was 5%).

On the other hand, the culture medium in which each strain was cultivated was mixed with an equal volume of MEM medium, and then filtered through a 0.22 탆 filter, and 10 쨉 l was administered to each well (final concentration of the culture medium was 5%).

The ability of each of the fermentation broth filters to inhibit the growth of viruses was measured according to the method disclosed in Korean Patent No. 682069, After completion of the virus infection test, 100 μl of 10% TCA (trichloroacetic acid) was added to each well, followed by incubation at 4 ° C for 1 hour and washing with distilled water several times. After drying at room temperature, 100 μl of 0.4% (w / v) SRB (sulforhodamine B) solution dissolved in 1% (v / v) acetic acid was added and stained for 30 minutes. The SRB staining solution not bound to the cells was washed several times with 1% (v / v) acetic acid and dried again. 100 μl of a 10 mM Tris solution (pH 10.5) was added to each well to sufficiently dissolve the stain associated with the cells, and the absorbance was measured at 560 nm. Each treatment group was labeled with the virus-free group (A), the fermentation liquid filter only group [B], the virus-only group [C] The cell viability (%) of the fermentation broth was calculated by the following formula (1) and the inhibitory effect on the virus growth of the fermentation broth filter solution (%). The results are shown as the mean value and the standard deviation of the results of three experiments performed under the same conditions.

Cell viability (%) and virus proliferation inhibitory ability (%) at 5% concentration of each filter liquid or culture medium were determined and shown in Table 1 (cell viability) and Table 2 (virus proliferation inhibitory ability).

Cell viability of Vero cells in non-treated group of fermentation broth filtrate and culture division(%) Cell survival rate Untreated group Fermentation liquid filter liquid MDR medium Vero cells 104.00 ± 7.21 100.13 + - 2.12 97.05 ± 0.99 NIH3T3 cells 104.00 + - 8.23 99.09 + 2.04 104.34 + - 8.23 MDCK cells 99.50 ± 2.15 104.14 + - 3.07 99.50 ± 2.15

As shown in Table 1, the cell solution used for the virus infection test showed a cell survival rate of 95 to 109% at a concentration of 5% in the fermentation broth and the culture solution, .

division(%) Uninfected group Infected group Untreated group Kozaki A16 Kozaki B3 Cozaki B4 Culture solution 99.72 + 1.87 0.00 ± 12.60 0.60 + - 2.34 2.44 ± 4.46 9.14 + - 2.55 Pan ram root extract 100.56 + - 2.52 0.00 ± 12.60 18.32 + - 0.50 32.75 + - 3.51 9.90 ± 1.28 Extract liquid 104.34 + - 8.23 0.00 ± 12.60 58.49 + - 4.76 87.98 + - 3.53 80.27 + - 6.58

As shown in Table 2, the filtrate of the fermentation broth of the Root Root Root Extract solution showed a suppressive effect of 58.4% or more in the case of the Kosaki virus A16 type and 87.9% or more in the case of the Kosaki virus type B3 at a concentration of 1/20 (5%) . In contrast, the inhibitory effect of Kosaki virus B4 type was over 80.3%. The culture medium showed inhibition of 0.60% in Kosaki virus A16 type and 2.44% or more in Kosaki virus type B3, 9.14 %, And showed 20 ~ 50 times more antiviral activity than the fermentation broth. In the case of Kosaki virus A16, the inhibitory effect was more than 18.32%. In the case of Kosaki virus type B3, the inhibitory effect was more than 32.75%. In case of Kosaki virus type B4, the inhibitory effect was more than 9.9% The antiviral activity was 2 ~ 9 times better than the simple extract which was not fermented.

Example 2: Antiviral ability test of fermented liquid filter solution against enterovirus

To measure the ability of the fermentation broth filter to inhibit virus growth, 2 × 10 ⁴ Vero cells were placed in each well of a 96-well plate and cultured for 24 hours. After 24 hours, the culture supernatant of each well was removed, and 90 μl of EV71 virus solution diluted to a TCID of 50 was added to each well. Then, 10 μl of the fermentation broth mixed with the fermentation broth prepared in Reference Example 2 was added to each well (Final concentration of fermentation broth filtrate: 5%).

On the other hand, the culture medium in which each strain was cultivated was mixed with an equal volume of MEM medium, and then filtered through a 0.22 탆 filter, and 10 쨉 l was administered to each well (final concentration of the culture medium was 5%).

The ability of each of the fermentation broth filters to inhibit the growth of viruses was measured according to the method disclosed in Korean Patent No. 682069, After completion of the virus infection test, 100 μl of 10% TCA (trichloroacetic acid) was added to each well, followed by incubation at 4 ° C for 1 hour and washing with distilled water several times. After drying at room temperature, 100 μl of 0.4% (w / v) SRB (sulforhodamine B) solution dissolved in 1% (v / v) acetic acid was added and stained for 30 minutes. The SRB staining solution not bound to the cells was washed several times with 1% (v / v) acetic acid and dried again. 100 μl of a 10 mM Tris solution (pH 10.5) was added to each well to sufficiently dissolve the stain associated with the cells, and the absorbance was measured at 560 nm. Each treatment group was labeled with the virus-free group (A), the fermentation liquid filter only group [B], the virus-only group [C] The cell viability (%) of the fermentation broth was calculated by the following formula (1) and the inhibitory effect on the virus growth of the fermentation broth filter solution (%). The results are shown as the mean value and the standard deviation of the results of three experiments performed under the same conditions.

division(%) Uninfected group Infected group Untreated group EV71 Culture solution 99.72 + 1.87 0.00 ± 12.60 11.47 ± 1.25 Pan ram root extract 100.56 + - 2.52 0.00 ± 12.60 21.85 ± 1.71 Extract liquid 104.34 + - 8.23 0.00 ± 12.60 92.74 + 1.63

As shown in Table 3, the filtrate of the fermentation broth of the Root Root Extract showed a inhibitory effect of 92.74% or more on the enterovirus EV71 at a concentration of 1/20 (5%), and the culture medium had a inhibitory effect of 11.47% in the enterovirus EV71 The filtrate of the fermentation broth showed 8 times more antiviral activity than the culture solution. In the case of only the extract of Pan - ram root roots, the inhibitory effect of enterovirus EV71 was over 21.85%, and the fermentation broth was superior to the non - fermented simple extract by four times.

Example 3: Antiviral ability test of filter liquid of fermentation broth against influenza virus

In order to measure the inhibitory effect of the fermentation broth filtrate on virus proliferation, 2 × 10 ⁴ MDCK (Madin-Darby canine kidney) cells were placed in each well of a 96-well plate and cultured for 24 hours. After 24 hours, the culture supernatant of each well was removed, and two kinds of influenza A virus (A / WS / 33, A / PR / 8/34) diluted to TCID 50 and one influenza B virus / 40) solution was added to each well, and then 10 μl of the fermentation broth solution solution mixture prepared in Reference Example 2 was added to each well (final concentration of the fermentation broth solution was 5%).

On the other hand, the culture medium in which each strain was cultivated was mixed with an equal volume of MEM medium, and then filtered through a 0.22 탆 filter, and 10 쨉 l was administered to each well (final concentration of the culture medium was 5%).

The ability of each of the fermentation broth filters to inhibit the growth of viruses was measured according to the method disclosed in Korean Patent No. 682069, After completion of the virus infection test, 100 μl of 10% TCA (trichloroacetic acid) was added to each well, followed by incubation at 4 ° C for 1 hour and washing with distilled water several times. After drying at room temperature, 100 μl of 0.4% (w / v) SRB (sulforhodamine B) solution dissolved in 1% (v / v) acetic acid was added and stained for 30 minutes. The SRB staining solution not bound to the cells was washed several times with 1% (v / v) acetic acid and dried again. 100 μl of a 10 mM Tris solution (pH 10.5) was added to each well to sufficiently dissolve the stain associated with the cells, and the absorbance was measured at 560 nm. Each treatment group was labeled with the virus-free group (A), the fermentation liquid filter only group [B], the virus-only group [C] The cell viability (%) of the fermentation broth was calculated by the following formula (1) and the inhibitory effect on the virus growth of the fermentation broth filter solution (%). The results are shown as the mean value and the standard deviation of the results of three experiments performed under the same conditions.

division(%) Uninfected group Infected group Untreated group A / PR / 8/34 A / WS / 33 B / Lee / 40 Culture solution 113.77 + - 8.15 0.00 ± 11.80 0.60 + - 2.34 2.44 ± 4.46 9.14 + - 2.55 Pan ram root extract 114.30 ± 3.77 0.00 ± 12.60 18.32 + - 0.50 32.75 + - 3.51 9.90 ± 1.28 Extract liquid 99.17 ± 5.919 0.00 ± 13.0 58.49 + - 4.76 87.98 + - 3.53 80.27 + - 6.58

As shown in Table 3, the filtrate of the fermentation broth extract of Panamba root extract showed 58 ~ 88% inhibitory effect on influenza virus at a concentration of 1/20 (5%), and the culture medium contained 0.6 ~ 9.14% The fermentation broth showed antiviral activity 7 ~ 90 times higher than that of culture broth. When the extract of Pan Ram Root Extract was treated only, the inhibitory effect was over 9.9 ~ 32.75%. The fermented broth filtrate showed 1.7 ~ 8 times more antiviral activity than non - fermented simple extract.

Example 4: Antiviral potency test of a fermented liquor for coronavirus

To measure the ability of the fermentation broth filter to inhibit virus growth, 2 × 10 ⁴ Vero cells were placed in each well of a 96-well plate and cultured for 24 hours. After 24 hours, the culture supernatant of each well was removed, and 90 μl of PEDV virus solution diluted to a TCID of 50 was added to each well. Then, 10 μl of the fermentation broth filtrate solution mixture prepared in Reference Example 2 was administered to each well (Final concentration of fermentation broth filtrate: 5%).

On the other hand, the culture medium in which each strain was cultivated was mixed with an equal volume of MEM medium, and then filtered through a 0.22 탆 filter, and 10 쨉 l was administered to each well (final concentration of the culture medium was 5%).

The ability of each of the fermentation broth filters to inhibit the growth of viruses was measured according to the method disclosed in Korean Patent No. 682069, After completion of the virus infection test, 100 μl of 10% TCA (trichloroacetic acid) was added to each well, followed by incubation at 4 ° C for 1 hour and washing with distilled water several times. After drying at room temperature, 100 μl of 0.4% (w / v) SRB (sulforhodamine B) solution dissolved in 1% (v / v) acetic acid was added and stained for 30 minutes. The SRB staining solution not bound to the cells was washed several times with 1% (v / v) acetic acid and dried again. 100 μl of a 10 mM Tris solution (pH 10.5) was added to each well to sufficiently dissolve the stain associated with the cells, and the absorbance was measured at 560 nm. Each treatment group was labeled with the virus-free group (A), the fermentation liquid filter only group [B], the virus-only group [C] The cell viability (%) of the fermentation broth was calculated by the following formula (1) and the inhibitory effect on the virus growth of the fermentation broth filter solution (%). The results are shown as the mean value and the standard deviation of the results of three experiments performed under the same conditions.

division(%) Uninfected group Infected group Untreated group PEDV Culture solution 99.72 + 1.87 0.00 ± 12.60 0.00 ± 21.50 Pan ram root extract 97.05 ± 0.99 0.00 ± 21.50 11.80 ± 12.00 Extract liquid 99.50 ± 2.15 0.00 ± 12.60 97.05 ± 0.99

As shown in Table 3, the fermented broth extract solution showed a inhibitory effect of 97.05% or more at a concentration of 1/20 (5%), and the culture broth had a inhibitory effect of 11.47% Fold more antiviral activity. The fermented broth filtrate showed antiviral activity more than 7 times higher than that of simple broth without fermentation.

Example 5: Antiviral potency test of fermented liquor filter solution against herpes virus

To measure the inhibitory effect of the fermentation broth on virus proliferation, 2 × 10 ⁴ NIH3T3-E1 (muscle fibroblast) cells were placed in each well of a 96-well plate and cultured for 24 hours. After 24 hours, the culture supernatant of each well was removed, and 90 占 퐇 of two types of herpes simplex (HPV1, HPV2) and one kind of herpes zoster (diluted to TCID 50) were added to each well. 10 [mu] L of the fermentation broth mixed solution solution prepared in Reference Example 2 was administered to each well (final concentration of the fermentation broth solution was 5%).

On the other hand, the culture medium in which each strain was cultivated was mixed with an equal volume of MEM medium, and then filtered through a 0.22 탆 filter, and 10 쨉 l was administered to each well (final concentration of the culture medium was 5%).

The ability of each of the fermentation broth filters to inhibit the growth of viruses was measured according to the method disclosed in Korean Patent No. 682069, After completion of the virus infection test, 100 μl of 10% TCA (trichloroacetic acid) was added to each well, followed by incubation at 4 ° C for 1 hour and washing with distilled water several times. After drying at room temperature, 100 μl of 0.4% (w / v) SRB (sulforhodamine B) solution dissolved in 1% (v / v) acetic acid was added and stained for 30 minutes. The SRB staining solution not bound to the cells was washed several times with 1% (v / v) acetic acid and dried again. 100 μl of a 10 mM Tris solution (pH 10.5) was added to each well to sufficiently dissolve the stain associated with the cells, and the absorbance was measured at 560 nm. Each treatment group was labeled with the virus-free group (A), the fermentation liquid filter only group [B], the virus-only group [C] The cell viability (%) of the fermentation broth was calculated by the following formula (1) and the inhibitory effect on the virus growth of the fermentation broth filter solution (%). The results are shown as the mean value and the standard deviation of the results of three experiments performed under the same conditions.

division(%) Uninfected group Infected group Untreated group HPV1 HPV2 Zoster Culture solution 113.77 + - 8.15 0.00 ± 11.80 0.60 + - 2.34 2.44 ± 4.46 9.14 + - 2.55 Pan ram root extract 114.30 ± 3.77 0.00 ± 12.60 18.32 + - 0.50 32.75 + - 3.51 9.90 ± 1.28 Extract liquid 99.17 ± 5.919 0.00 ± 13.0 58.49 + - 4.76 87.98 + - 3.53 80.27 + - 6.58

As shown in Table 3, the filtrate of the fermentation broth of the Root Root Root Extract showed a suppressive effect of 58 ~ 88% or more on the herpes virus at a concentration of 1/20 (5%), and the inhibitory effect was 0.6 ~ 9.14% The filtrate of the fermentation broth showed 7 ~ 90 times more antiviral activity than the culture broth. When the extract of Pan Ram Root Extract was treated only, the inhibitory effect was over 9.9 ~ 32.75%. The fermented broth filtrate showed 1.7 ~ 8 times more antiviral activity than non - fermented simple extract.

Formulation Example 1: Preparation of cosmetics

number Raw material name Prescription Example 1 One Purified water Balance 2 1,3-butylene glycol 4.0 3 Disodium edetate 0.1 4 Phage-PPE 18/4 copolymer 1.0 5 Di-panthenol 0.1 6 Methyl paraben 0.2 7 ethanol 8 8 Pfizy-26-Butes-26 / Phage-40 Hardened Pf
Ma 0.5 9 incense Suitable amount 10 Root Root Extract Fermentation Liquor 25

<Manufacturing Method>

1) Raw materials of Nos. 2, 3 and 4 were weighed, and purified water of No. 1 was added thereto and dissolved by stirring at room temperature.

2) The raw materials of Nos. 5, 6, 7, 8 and 9 were weighed, dissolved by stirring, and added to 1).

3) The solution of the fermentation broth of Root Root Root Extract No. 10 was added and dissolved, and the solution was added to the above 1), stirred appropriately and filtered to prepare a cosmetic product.

Claims (7)

A composition for preventing and treating viral infection, which comprises a fermentation broth obtained by fermenting Root Root Root Extract as an active ingredient. The composition for preventing and treating viral infection according to claim 1, wherein the fermentation comprises a fermentation broth obtained by fermenting a root extract of Root Root Root using yeast. The composition according to claim 1, wherein the virus is at least one virus selected from the group consisting of herpes simplex virus, herpes simplex virus, coronavirus, Kosaki virus, enterovirus or influenza virus. The composition for preventing and treating viral infection according to claim 1, wherein the virus infection and the treatment prevent the virus from adhering to the cell membrane of the mammalian cell The antiviral cosmetic according to claim 1, wherein the fermentation liquid is contained as an active ingredient The antiviral cosmetic product according to claim 4, wherein the fermentation liquid is at least 25% by weight of the total weight. The health supplement according to claim 1, wherein the fermentation liquid is contained as an active ingredient.

Images